For the year ending 2025-12-31, CTSO has $44,182K in assets. $38,279K in debts. $6,249K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 6,249 | |||
| Accounts receivable, net of allowances of 164 and 158 at december 31, 2025 and 2024, respectively | 7,550 | |||
| Inventories - net | 5,281 | |||
| Prepaid expenses and other current assets | 1,554 | |||
| Total current assets | 20,634 | |||
| Property and equipment - net | 7,823 | |||
| Restricted cash | 1,522 | |||
| Right-of-use asset | 10,924 | |||
| Patents - net | 3,226 | |||
| Other assets | 53 | |||
| Total assets | 44,182 | |||
| Accounts payable | 2,869 | |||
| Accrued expenses and other current liabilities | 6,299 | |||
| Lease liability - current portion | 541 | |||
| Total current liabilities | 9,709 | |||
| Lease liability, net of current portion | 11,903 | |||
| Long-term debt, net of debt discount | 16,667 | |||
| Total liabilities | 38,279 | |||
| Common stock, par value 0.001, 100,000,000 shares authorized and 62,804,305 and 54,830,146 shares issued and outstanding at december 31, 2025 and 2024, respectively | 63 | |||
| Additional paid-in capital | 321,024 | |||
| Accumulated other comprehensive income (loss) | -2,977 | |||
| Accumulated deficit | -312,207 | |||
| Total stockholders' equity | 5,903 | |||
| Total liabilities and stockholders' equity | 44,182 | |||
Cytosorbents Corp (CTSO)
Cytosorbents Corp (CTSO)